Galapagos (GLPG) Q2 2024 earnings summary

Executive summary

• Transitioned to a pure-play biotech focused on oncology and immunology, divesting Jyseleca® to Alfasigma to sharpen strategic focus and secure future milestone/royalty potential.

• Advanced a revitalized pipeline with over 20 small molecule and cell therapy programs, including key clinical and regulatory milestones for CAR-T candidates and new collaborations with Adaptimmune and BridGene.

• Expanded cell therapy manufacturing network, notably through a U.S. partnership with Blood Centers of America, and invested in decentralized manufacturing capabilities.

• Maintained a robust cash position of €3.43 billion as of June 30, 2024, supporting R&D, business development, and future collaborations.

• Achieved net profit of €99.2 million for H1 2024, driven by the Jyseleca® sale and strong financial income.

Financial highlights

• Total net revenues from continuing operations for H1 2024 were €140.3 million, up 18% year-over-year, mainly from the Gilead collaboration and Jyseleca® supply.

• Net profit reached €99.2 million, including €71 million from discontinued operations and €49.5 million in fair value adjustments and currency gains.

• R&D expenses increased 34% to €145.2 million, reflecting oncology and small molecule investments.

• Operational cash burn for H1 2024 was €250 million, with updated full-year guidance of €370–410 million including business development.

• Cash and current financial investments totaled €3.43 billion at June 30, 2024.

Outlook and guidance

• 2024 cash burn guidance reaffirmed at €280–320 million excluding business development; updated to €370–410 million including recent deals.

• Plans to initiate at least four IND/CTA-enabling studies and one first-in-human study in 2025, and to add at least two new clinical assets annually from 2026.

• Focused on regulatory progress for CAR-T trials, expanding manufacturing sites, and signing new collaborations.

• Key pipeline milestones and clinical data readouts remain on track for the remainder of 2024.